

James Campbell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/840648/publications.pdf>

Version: 2024-02-01

31
papers

3,023
citations

304743

22
h-index

434195

31
g-index

36
all docs

36
docs citations

36
times ranked

6299
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. <i>Gut</i> , 2018, 67, 1780-1792.	12.1	19
2	Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. <i>Nature Communications</i> , 2018, 9, 2016.	12.8	22
3	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. <i>Scientific Reports</i> , 2018, 8, 10614.	3.3	13
4	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. <i>Nature Communications</i> , 2018, 9, 1849.	12.8	310
5	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. <i>Scientific Data</i> , 2017, 4, 170020.	5.3	14
6	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2022-2034.	4.1	66
7	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. <i>British Journal of Cancer</i> , 2017, 117, 113-123.	6.4	84
8	ATR Is a Therapeutic Target in Synovial Sarcoma. <i>Cancer Research</i> , 2017, 77, 7014-7026.	0.9	43
9	CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. <i>Cell Systems</i> , 2017, 5, 82-86.e3.	6.2	5
10	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. <i>PLoS ONE</i> , 2016, 11, e0149099.	2.5	60
11	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. <i>Nature Communications</i> , 2016, 7, 13837.	12.8	272
12	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016, 6, 838-851.	9.4	222
13	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. <i>Cell Reports</i> , 2016, 14, 2490-2501.	6.4	97
14	Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1472-1484.	4.1	73
15	Pervasive and opposing effects of Unpredictable Chronic Mild Stress (UCMS) on hippocampal gene expression in BALB/cj and C57BL/6j mouse strains. <i>BMC Genomics</i> , 2015, 16, 262.	2.8	30
16	Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity. <i>Cancer Research</i> , 2014, 74, 287-297.	0.9	290
17	Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 320-328.	2.4	24
18	Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	7.0	126

#	ARTICLE	IF	CITATIONS
19	Secondary mutations in <i>BRCA2</i> associated with clinical resistance to a <i>PARP</i> inhibitor. <i>Journal of Pathology</i> , 2013, 229, 422-429.	4.5	287
20	Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in <i>FGFR3</i> -Mutant Cancer. <i>Cancer Discovery</i> , 2013, 3, 1058-1071.	9.4	103
21	A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity. <i>PLoS ONE</i> , 2013, 8, e61520.	2.5	147
22	Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. <i>Proteomics</i> , 2012, 12, 2355-2365.	2.2	18
23	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e28527.	2.5	106
24	Proteome-Based Plasma Markers of Brain Amyloid- β^2 Deposition in Non-Demented Older Individuals. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1099-1109.	2.6	69
25	Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. <i>Proteomics</i> , 2011, 11, 1148-1152.	2.2	34
26	Plasma Gelsolin is Decreased and Correlates with Rate of Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 585-596.	2.6	69
27	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2010, 67, 739.	12.3	353
28	Comparison of a Protein-Level and Peptide-Level Labeling Strategy for Quantitative Proteomics of Synaptosomes Using Isobaric Tags. <i>Journal of Proteome Research</i> , 2010, 9, 2725-2733.	3.7	26
29	Proteomics for Brain Disorders—The Promise for Biomarkers. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 68-74.	3.8	4
30	Candidate verification of iron-regulated <i>Neisseria meningitidis</i> proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring. <i>Journal of Proteomics</i> , 2009, 73, 231-239.	2.4	27
31	A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma. <i>Proteomics</i> , 2005, 5, 3040-3044.	2.2	9